Literature DB >> 35013705

Application of Bayesian spatial-temporal models for estimating unrecognized COVID-19 deaths in the United States.

Yuzi Zhang1, Howard H Chang1, A Danielle Iuliano2, Carrie Reed2.   

Abstract

In the United States, COVID-19 has become a leading cause of death since 2020. However, the number of COVID-19 deaths reported from death certificates is likely to represent an underestimate of the total deaths related to SARS-CoV-2 infections. Estimating those deaths not captured through death certificates is important to understanding the full burden of COVID-19 on mortality. In this work, we explored enhancements to an existing approach by employing Bayesian hierarchical models to estimate unrecognized deaths attributed to COVID-19 using weekly state-level COVID-19 viral surveillance and mortality data in the United States from March 2020 to April 2021. We demonstrated our model using those aged ≥ 85 years who died. First, we used a spatial-temporal binomial regression model to estimate the percent of positive SARS-CoV-2 test results. A spatial-temporal negative-binomial model was then used to estimate unrecognized COVID-19 deaths by exploiting the spatial-temporal association between SARS-CoV-2 percent positive and all-cause mortality counts using an excess mortality approach. Computationally efficient Bayesian inference was accomplished via the Polya-Gamma representation of the binomial and negative-binomial models. Among those aged ≥ 85 years, we estimated 58,200 (95% CI: 51,300, 64,900) unrecognized COVID-19 deaths, which accounts for 26% (95% CI: 24%, 29%) of total COVID-19 deaths in this age group. Our modeling results suggest that COVID-19 mortality and the proportion of unrecognized deaths among deaths attributed to COVID-19 vary by time and across states.
© 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bayesian hierarchical modeling; COVID-19; Excess mortality; Spatial–temporal modeling

Year:  2022        PMID: 35013705      PMCID: PMC8730676          DOI: 10.1016/j.spasta.2021.100584

Source DB:  PubMed          Journal:  Spat Stat


Introduction

The Coronavirus Disease 19 (COVID-19) pandemic caused by the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has profoundly affected the world. It is reported that at least 771,000 people have died from COVID-19 in the United States as of November 23, 2021 (Centers for Disease Control and Prevention, 2021). This statistic is based on COVID-19 death data reported by state and county-level jurisdictions to the Centers for Disease Control and Prevention (CDC) and provisional death counts from the National Center for Health Statistics (NCHS). Currently, COVID-19 cases, hospitalizations, and deaths are nationally notifiable and captured by the National Notifiable Disease Surveillance System (NNDSS). However, as noted in previous studies, reporting is unlikely to capture all deaths related to SARS-CoV-2 infections (Woolf et al., 2020, Woolf et al., 2021, Rossen et al., 2020, Rivera et al., 2020, Iuliano et al., 2021). Deaths may not be reported because of delays in reporting, failure to access medical care, false negative test results, or the cause of death being coded as a comorbid condition or a complication of COVID-19 (Vandoros, 2020). There is a pressing need to develop methods to estimate unrecognized deaths attributable to COVID-19. Accurate health burden estimates can guide allocation of public health resources, provide insights into spatial and temporal disease trends, and help in communicating effective prevention messages. During the COVID-19 pandemic, an excess mortality approach has been widely adapted to estimate deaths attributable to COVID-19 (Woolf et al., 2020, Weinberger et al., 2020, Rivera et al., 2020, Rossen et al., 2020). This method has also been used for estimating deaths associated with other infectious diseases, including influenza, pneumonia, and hepatitis C virus infections (Cohen et al., 2010, Lin and Nichol, 2001, Neal, 2007). A critical component of the excess mortality approach is the estimation of baseline deaths (i.e., the number of deaths assuming there is no SARS-CoV-2 mortality). Total COVID-19 deaths are derived from comparing the estimated baseline deaths to observed deaths during the pandemic. In previous studies of COVID-19 deaths, various models have been used to estimate baseline deaths (Tatar et al., 2021, Vandoros, 2020). For example, Woolf et al., 2020, Weinberger et al., 2020, and Rivera et al. (2020) all used Poisson regression models with different covariates. More recently, a linear mixed model that accounts for temporal correlations in weekly mortality data was used in Belgium and the Netherlands (Verbeeck et al., 2021). Notably, the majority of previous studies estimated baseline deaths relying solely on pre-pandemic mortality data, making the assumption that historical mortality trends remain unchanged during the pandemic. In a recent work by Iuliano et al. (2021), the number of baseline deaths is estimated by leveraging proxy data on infection activity, specifically the percent of positive SARS-CoV-2 test results. This approach models weekly all-cause deaths during the pandemic, after removing known COVID-19 deaths, as a function of lagged weekly percent positive. The main objective of our analysis was to extend the approach by Iuliano et al. (2021) in several important ways. First, we addressed the issue of small numbers of SARS-CoV-2 tests in the early phase of the outbreak by modeling positive test results using a Bayesian spatial–temporal binomial model to borrow information across geographical regions and epidemic weeks. Second, we evaluated the importance of propagating uncertainties in estimated percent positive in subsequent mortality analyses. Third, we examined the use of a spatial–temporal negative binomial model to estimate baseline mortality and unrecognized COVID-19 deaths; previous analyses often ignored potential spatial dependence. Finally, we applied the modeling framework to analyze weekly US COVID-19 deaths and surveillance data for the population ages years in the 48 contiguous US states and the District of Columbia. This age group was chosen to demonstrate this model because it had the largest COVID-19 mortality burden as measured by both total death counts and death rate previous estimated by Iuliano et al. (2021).

Data

All-cause and COVID-19 deaths, coded using International Classification of Diseases, 10th Edition (ICD-10), were extracted from the National Vital Statistics System (NVSS) for the population years of age between March 22, 2020 to April 25, 2021. Data were aggregated by epidemiologic week and by state, including the 48 contiguous states and the District of Columbia (DC). We used epidemiologic week defined by the National Notifiable Disease Surveillance System (NNDSS) for the purpose of reporting weekly disease incidence. We excluded Alaska and Hawaii in this analysis because these two states do not share spatial adjacency with other states. We adjusted for possible delays in reporting following the approach described elsewhere (Iuliano et al., 2021). Weekly state-specific SARS-CoV-2 surveillance data (i.e., number of tests and number of positive results) were obtained from multiple surveillance systems including the Electronic Surveillance System for the Early Notification of Community-based Epidemics (ESSENCE), Public Health Laboratory Interoperability Project (PHLIP), and Public Health Laboratory Information System 2 (PHLIS2) (Thompson et al., 2010) from March 8, 2020 to April 25, 2021. Two extra epidemiologic weeks of surveillance data were needed for SARS-CoV-2 testing to include the lagged percent positive in estimating unrecognized COVID-19 deaths. Census population data for 2019 were obtained from the United States Census Bureau (U.S. Census Bureau, 2019). In total, 1,134,371 all-cause deaths were extracted among those years of age, of which 162,086 (14.2%) were coded as deaths attributed to COVID-19 (ICD-10 U07.1). For SARS-CoV-2 surveillance data, a total of 2,286,472 tests were identified, of which 124,600 (5.4%) were SARS-CoV-2 positive. Summary statistics of state-level surveillance and mortality data are presented in Supplementary Table S1.

Methods

Spatial–temporal binomial models for positive tests

Let denote the number of positive SARS-CoV-2 test results for state during week with and . We assume , where is the percent of positive SARS-CoV-2 test results in decimal form and is the number of tests conducted. In subsequent excess mortality analyses, estimates of are used to reflect spatial–temporal variations in infection activity. We model on the logistic scale: where is the intercept and denotes a mean-zero spatial–temporal Gaussian process. We consider three forms for . First, we assume an additive model where denotes exchangeable state-specific random effects and denotes week-specific random effects. Temporal dependence in is modeled via a 1-dimensional proper conditional autoregressive model (CAR), . Specifically, the joint distribution of is mean-zero multivariate Normal with covariance matrix given by , where is a symmetric matrix with the entry equal to 1 if week and are adjacent, and 0 otherwise; and is a diagonal matrix with . This is also known as a random walk model of order 1 and parameter controls the degree of temporal dependence between weeks. Second, we extend the above additive model by allowing state-specific random effects to also follow a CAR model, . To induce spatial dependency in neighboring states, we set entries of the adjacency matrix to be 1 if two states share some common boundary. Third, we consider a non-additive spatial–temporal process using a dynamic model for time-series of spatial processes (Banerjee et al., 2003): where is the temporal autoregressive parameter and are week-specific spatial residuals with , which we model similarly using the same between-state adjacency matrix. Hereafter, we refer to the above three specifications of the spatial–temporal process as (A) exchangeable, (B) spatial, and (C) dynamic.

Spatial–temporal negative-binomial models for mortality

To estimate unrecognized COVID-19 deaths, our mortality models are developed using only the subset of all-cause deaths that are not classified on death certificates as being caused by COVID-19. Let denote the number of all-cause deaths with COVID-19 coded deaths removed for state during week . Negative-binomial (NB) models are used to account for overdispersion often observed in death counts. To facilitate estimation and interpretation, we adapt the parametrization used in Pillow and Scott (2012) and Neelon (2019). Specifically, the NB model is parametrized as a hierarchical Poisson model and has the following form: where is the overdispersion parameter. The corresponding expectation and variance of are given by and , respectively. Spatial–temporal variations are described by the log-linear mean model where is the at-risk populations size and enters the model as an offset, is the intercept, and are 1-week and 2-week lagged percent of positive SARS-CoV-2 test results, and is a mean-zero spatial–temporal process. Similar to the spatial–temporal binomial test-positive models in Section 3.1, we consider three forms of : (A) space–time additive with exchangeable state-specific random effects; (B) space–time additive with spatial state-specific CAR random effects; (C) dynamic spatial model. Based on the excess mortality approach, the weekly number of unrecognized deaths attributed to SARS-CoV-2 transmission is defined as the difference between (1) expected deaths with observed SARS-CoV-2 circulation, and (2) counterfactual expected deaths assuming there is no SARS-CoV-2 circulation (i.e., setting and to 0). Hence for state during week , the number of unrecognized deaths is defined as We note that the above quantity represents estimated COVID-19 deaths only among all-cause death that were not classified on deaths certificates as being caused by COVID-19. The total number of COVID-19 deaths can be obtained by adding estimated unrecognized COVID-19 deaths and COVID-19 reported deaths from death certificates.

Estimation and inference

We employed a two-stage Bayesian estimation procedure. First, percent positive was estimated from the spatial–temporal binomial test-positive model, and these estimates were used as covariates in the second-stage NB mortality model. To account for uncertainties in from the first-stage estimation, using multiple realizations of from their joint posterior distribution, we fitted separate NB mortality model and combined posterior samples of parameters. This approach is similar to conducting Bayesian analysis with multiple imputation advocated by Gelman et al. (1995). Parameter estimation in the spatial–temporal models was carried out via Markov Chain Monte Carlo (MCMC) using Gibbs sampling and Metropolis–Hastings (MH) algorithms. Particularly, the high-dimensional spatial and temporal random effects were handled by efficient Gibbs algorithms using the Polya-Gamma (PG) representation of binomial and NB models (Pillow and Scott, 2012, Polson et al., 2013). For the binomial test-positive models described in Section 3.1, all model parameters can be estimated using Gibbs sampling after specifying appropriate prior distributions and introducing PG latent random variables . Similarly, for the NB mortality model, we used latent variables of the form . The following prior distributions were used. Normal (0, 100) prior was assigned for all fixed effect regression coefficients (; inverse-Gamma (0.1, 0.1) priors were assigned for all variance parameters (); and discrete priors (i.e., 1000 equally spaced values between 0 and 1) were assigned for parameters , , and in CAR models. Details of the MCMC algorithm for fitting spatial–temporal binomial models and NB models are given in the Supplementary Materials. We used the widely available information criterion (WAIC) to select the form of the spatial–temporal random effects in the test-positive model and the mortality model. WAIC is a measure of predictive accuracy where lower WAIC value is preferred. We follow the definition presented in Banerjee et al. (2003) where WAIC is defined on the deviance scale. Multiple realizations of from the best test-positive model were used for selecting the best mortality model. All analyses were conducted using R 4.0.2 (R Core Team, 2021).

Results

WAIC from the fitted test-positive and mortality models with different forms of spatial–temporal processes are given in Table 1. Five sets of percent positive were imputed from their posterior distributions to fit the mortality model. We found that five imputations are sufficient to quantify related uncertainties. Specifically, in sensitivity analyses, increasing the number of imputations to 100 yielded similar 95% credible intervals (CIs) of predicted weekly deaths ( 0.1% difference in CI endpoints). For the test-positive model, the dynamic spatial–temporal random process which yielded the lowest WAIC is clearly preferred. This may reflect the importance of allowing the timings of when the epidemic started and peaked to vary across states. In contrast, for modeling death counts, the additive spatial and temporal random effects are preferred over the dynamic model, indicating that the temporal trend in baseline mortality rates is similar across states in the absence of SARS-CoV-2. We report COVID-19 death estimates from the spatial random effect specification (i.e., the Spatial model in Table 1) of the NB mortality model since three out of five imputed datasets yielded lower WAIC under this model.
Table 1

Widely available information criterion (WAIC) for the binomial test-positive model and negative-binomial (NB) mortality models with three different forms of spatial–temporal random effects.

ModelExchangeableaSpatialbDynamicc
Binomial model596995961918271

NB model

imputation 1260152604027943
imputation 2259492589527873
imputation 3258012592927719
imputation 4258872587727427
imputation 5256652557727957

Space–time additive with exchangeable state-specific random effects and week-specific proper conditional autoregressive model (CAR) random effects.

Space–time additive with state-specific CAR random effects and week-specific CAR random effects.

Dynamic spatial model.

Estimates of parameters included in the selected binomial test-positive and NB mortality models are presented in Tables S4 and S5. The temporal autoregressive parameter in the test-positive model was estimated to be 0.94 (95% CI: 0.93, 0.95), which indicates that the temporal dependence of the spatial process is strong. For the NB mortality model, we observed positive estimates of parameters associated percent positive at 1-week and 2-week lags (0.56 and 0.22), these estimates suggest that weekly all-cause deaths with COVID-19 deaths removed increased as percent positive increased. Two parameters included in CAR models controlling temporal and spatial dependence were estimated to be 0.99, which indicates that observed mortality data exhibited temporal and spatial dependence. We also note that the estimated overdispersion parameter is large (87.51 95% CI: 54.05, 148.06), implying small over-dispersion. This is likely because the mortality model contains week and state-specific random effects that explained residuals well. Widely available information criterion (WAIC) for the binomial test-positive model and negative-binomial (NB) mortality models with three different forms of spatial–temporal random effects. Space–time additive with exchangeable state-specific random effects and week-specific proper conditional autoregressive model (CAR) random effects. Space–time additive with state-specific CAR random effects and week-specific CAR random effects. Dynamic spatial model. Estimated weekly percent of positive SARA-CoV-2 test results from the binomial test-positive model with dynamic spatial random effects and maximum likelihood estimators of binomial mean from March 8, 2020 to April 25, 2021 in six states among populations aged years. The red areas represent the 95% Wald-type confidence interval band truncated at zero, the blue areas represent the 95% credible interval band. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) Fig. 1 displays the estimated percent positive from the dynamic test-positive model compared to a naive approach (i.e., maximum likelihood estimator [MLE]) for six selected states: Florida, Montana, Nebraska, New York, Oregon, and South Dakota. These six states were chosen to highlight between-state differences in the number of epidemic peaks and their timings, as well as model performance in states with different number of tests. In states with a large number of SARS-CoV-2 tests, estimates of percent positive from the two methods are nearly identical. For example, New York and Florida had, respectively, 136,324 and 80,007 tests conducted during the study time period (Fig. 1). However, for states where small number of tests were conducted (e.g., 4121 total tests in Nebraska) the dynamic test-positive model yielded smoother estimates along with narrower 95% CIs as compared to the naive approach. During early phases of the outbreak, the dynamic model can also provide percent positive estimates in states when there were no reported tests (e.g., South Dakota). The estimated state-specific weekly percent positive of all 48 contiguous states and DC are provided in Supplementary Materials.
Fig. 1

Estimated weekly percent of positive SARA-CoV-2 test results from the binomial test-positive model with dynamic spatial random effects and maximum likelihood estimators of binomial mean from March 8, 2020 to April 25, 2021 in six states among populations aged years. The red areas represent the 95% Wald-type confidence interval band truncated at zero, the blue areas represent the 95% credible interval band. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

The total number of unrecognized deaths attributed to COVID-19 during study period among populations aged years was estimated to be 58,200 (95% CI: 51,300, 64,900). This represents 26% of estimated total deaths attributable to COVID-19 (Table 2). The estimated COVID-19 death rate per 1000 population ranged from 18.0 to 44.4 across Health & Human Services (HHS) regions. The highest COVID-19 death rate (44.4, 95% CI: 43.4, 45.4) was observed in HHS Regions 2 (New Jersey and New York). As indicated in Table 2, although HHS Region 10 (Idaho, Oregon, and Washington) had the lowest COVID-19 death rate (18.0, 95% CI: 17.2, 18.8), this HHS Region suffered from the most under-counting; the estimated proportion of unrecognized COVID-19 deaths among all COVID-19 deaths is 0.35 (95% CI: 0.32, 0.38).
Table 2

Estimates of unrecognized COVID-19 deaths, COVID-19 death rate per 1000 population, and proportion of unrecognized COVID-19 deaths among estimated total COVID-19 deaths from March 22, 2020 to April 25, 2021 among populations aged years.

Reported COVID-19 Deaths among 85 years of ageaEstimated Number of Unrecognized COVID-19 Deaths among 85 years of age (95% CI)bEstimated COVID-19 Death Rate among 85 years of age per 1000 population (95% CI)Estimated Proportion of Unrecognized COVID-19 Deaths among 85 years of age (95% CI)c
HHS Regiond
1114302900 (2600, 3300)40.5 (39.5, 41.5)0.20 (0.18, 0.22)
2236445800 (5100, 6500)44.4 (43.4, 45.5)0.20 (0.18, 0.22)
3184196600 (5800, 7400)36.9 (35.7, 38.1)0.26 (0.24, 0.29)
42595612900 (11400, 14400)27.9 (26.8, 28.9)0.33 (0.30, 0.36)
5299329600 (8500, 10700)35.5 (34.4, 36.5)0.24 (0.22, 0.26)
6166057600 (6600, 8500)35.8 (34.4, 37.1)0.31 (0.29, 0.34)
783613100 (2700, 3500)35.8 (34.7, 37.0)0.27 (0.25, 0.29)
846891100 (900, 1200)28.2 (27.6, 28.9)0.19 (0.17, 0.21)
9201277000 (6200, 7900)28.4 (27.5, 29.3)0.26 (0.23, 0.28)
1029231600 (1400, 1800)18.0 (17.2, 18.8)0.35 (0.32, 0.38)

Totale16208558200 (51300, 64900)33.3 (32.3, 34.3)0.26 (0.24, 0.29)

Reported deaths coded as COVID-19 from the National Vital Statistics System (NVSS).

All values were rounded to their nearest hundred.

The proportion of estimated unrecognized COVID-19 deaths among estimated total COVID-19 deaths.

HHS Region 1 — CT, MA, ME, NH, RI, VT; HHS Region 2 — NJ, NY; HHS Region 3 — DC, DE, MD, PA, VA, WV; HHS Region 4 — AL, FL, GA, KY, MS, NC, SC, TN; HHS Region 5 — IL, IN, MI, MN, OH, WI; HHS Region 6 — AR, LA, NM, OK, TX; HHS Region 7 — IA, KS, MO, NE; HHS Region 8 — CO, MT, ND, SD, UT, WY; HHS Region 9 — AZ, CA, NV; HHS Region 10 — ID, OR, WA.

Across 48 contiguous states and DC.

Temporal trends of reported and predicted all-cause deaths with COVID-19 coded deaths removed on the national and the state-level are presented in Fig. 2(a) and Fig. 3, respectively. Although there is considerable variation in weekly counts at the state-level, our mortality model captures the temporal trend of reported death counts on the national level very well. The baseline mortality trend assuming there is no SARS-CoV-2 circulation (shown in green) can also be interpreted as the weekly expected death count that is not explained by variations in percent positive. In Fig. 2(a), as indicated by the vertical distance between predicted mortality counts (shown in red) and estimated baseline counts, there are a large number of unrecognized COVID-19 deaths in the first four weeks of the study period, followed by a decrease on the national level. This is further illustrated by examining the proportion of unrecognized COVID-19 deaths among all COVID-19 deaths, which is a measure of the degree of under-counting as shown in Fig. 2(b). This decrease may be related to the increasing availability of diagnostic testing for SARS-CoV-2. In Fig. 2(b), we also see that the proportion of unrecognized deaths is smaller when the total number of COVID-19 deaths is higher. Since the number of unrecognized deaths varies weekly, this indicates that unrecognized deaths contribute less to the total deaths compared to COVID-19 coded deaths.
Fig. 2

Time-series plot of (a) observed all-cause deaths with COVID-19 deaths removed (blue line), predicted all-cause deaths with COVID-19 deaths removed obtained from the selected negative-binomial mortality model (red line), and estimated expected deaths assuming there is no SARS-CoV-2 circulation (green line); (b) reported COVID-19 death rate per 1000 population (gray line), estimated COVID-19 death rate per 1000 population (black line), and estimated proportion of unrecognized COVID-19 deaths (blue line) across 48 contiguous states and DC from March 22, 2020 to April 25, 2021 among population aged years. Colored areas represent the corresponding 95% CIs. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Fig. 3

Time-series plot of observed all-cause deaths with COVID-19 deaths removed (blue line), predicted all-cause deaths with COVID-19 deaths removed obtained from the selected negative-binomial mortality model (red line), and estimated expected deaths assuming there is no SARA-CoV-2 circulation (green line) in six selected states from March 22, 2020 to April 25, 2021 among population aged years. Colored areas represent the corresponding 95% CIs. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Estimates of unrecognized COVID-19 deaths, COVID-19 death rate per 1000 population, and proportion of unrecognized COVID-19 deaths among estimated total COVID-19 deaths from March 22, 2020 to April 25, 2021 among populations aged years. Reported deaths coded as COVID-19 from the National Vital Statistics System (NVSS). All values were rounded to their nearest hundred. The proportion of estimated unrecognized COVID-19 deaths among estimated total COVID-19 deaths. HHS Region 1 — CT, MA, ME, NH, RI, VT; HHS Region 2 — NJ, NY; HHS Region 3 — DC, DE, MD, PA, VA, WV; HHS Region 4 — AL, FL, GA, KY, MS, NC, SC, TN; HHS Region 5 — IL, IN, MI, MN, OH, WI; HHS Region 6 — AR, LA, NM, OK, TX; HHS Region 7 — IA, KS, MO, NE; HHS Region 8 — CO, MT, ND, SD, UT, WY; HHS Region 9 — AZ, CA, NV; HHS Region 10 — ID, OR, WA. Across 48 contiguous states and DC. The estimated COVID-19 death rate presented in Fig. 2(b) shows a clear seasonal pattern, two distinct peaks appeared in the end of April 2020 and the beginning of January 2021. Temporal patterns of COVID-19 death rate and proportion of unrecognized deaths among estimated deaths attributable to COVID-19 varied by state as shown in Fig. 4. For example, we estimated a spike appearing around November 2020 in Montana, South Dakota, and Nebraska for COVID-19 death rate. However, a spike was not observed in New York. We also found that in New York and South Dakota, the proportion of unrecognized deaths among estimated deaths attributable to COVID-19 is stable and relatively low (around 0.10) after October 2020. Another example is the sudden increase in Nebraska in April 2021 that was not observed in other states. Temporal trends in COVID-19 death rate and proportion of unrecognized deaths for individual states are available in the Supplementary Materials.
Fig. 4

Time-series plot of reported COVID-19 death rate per 1000 population (gray line), estimated COVID-19 death rate per 1000 population (black line), and estimated proportion of unrecognized COVID-19 deaths (blue line) in six selected states from March 22, 2020 to April 25, 2021 among population aged years. Colored areas represent the corresponding 95% CIs. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Time-series plot of (a) observed all-cause deaths with COVID-19 deaths removed (blue line), predicted all-cause deaths with COVID-19 deaths removed obtained from the selected negative-binomial mortality model (red line), and estimated expected deaths assuming there is no SARS-CoV-2 circulation (green line); (b) reported COVID-19 death rate per 1000 population (gray line), estimated COVID-19 death rate per 1000 population (black line), and estimated proportion of unrecognized COVID-19 deaths (blue line) across 48 contiguous states and DC from March 22, 2020 to April 25, 2021 among population aged years. Colored areas represent the corresponding 95% CIs. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) Time-series plot of observed all-cause deaths with COVID-19 deaths removed (blue line), predicted all-cause deaths with COVID-19 deaths removed obtained from the selected negative-binomial mortality model (red line), and estimated expected deaths assuming there is no SARA-CoV-2 circulation (green line) in six selected states from March 22, 2020 to April 25, 2021 among population aged years. Colored areas represent the corresponding 95% CIs. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) Spatial heterogeneity of the COVID-19 death rate and proportion of unrecognized COVID-19 deaths is evident in Fig. 5. During the study period, six states located in the northeast U.S. (Connecticut, Massachusetts, New Jersey, New York, Pennsylvania, and Rhode Island) had notably high estimated COVID-19 death rates, ranging from 42.6 to 50.4 per 1000 population, and among which Rhode Island had the highest COVID-19 death rate (50.4, 95% CI: 49.4, 51.5). High estimated COVID-19 death rates were also observed in two midwestern adjacent states (South Dakota and Nebraska). We estimated that states varied substantially in the degree of under-counting of deaths attributable to COVID-19 (Fig. 5(b)). For example, Oregon had the highest proportion of unrecognized COVID-19 deaths (0.46, 95% CI: 0.42, 0.50).
Fig. 5

A map of (a) estimated COVID-19 death rate per 1000 population; (b) estimated proportion of unrecognized COVID-19 deaths across 48 contiguous states with state borders from March 22, 2020 to April 25, 2021 among population aged years.

Time-series plot of reported COVID-19 death rate per 1000 population (gray line), estimated COVID-19 death rate per 1000 population (black line), and estimated proportion of unrecognized COVID-19 deaths (blue line) in six selected states from March 22, 2020 to April 25, 2021 among population aged years. Colored areas represent the corresponding 95% CIs. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) A map of (a) estimated COVID-19 death rate per 1000 population; (b) estimated proportion of unrecognized COVID-19 deaths across 48 contiguous states with state borders from March 22, 2020 to April 25, 2021 among population aged years.

Discussion

In this paper, we describe a two-stage spatial–temporal modeling framework to estimate unrecognized deaths attributable to COVID-19. To model all-cause deaths not coded as COVID-19, we adapted a negative-binomial model that accounts for infection activity by including estimated percent positive at 1-week and 2-week lags. The spatial–temporal binomial model improves the estimation of percent positive especially when there were few or no reported tests in the early phase of outbreak. Our modeling framework aims to incorporate the statistical uncertainty resulting from the first-stage estimation, allows for overdispersion in mortality counts, accounts for spatial–temporal dependence, and facilitates the inference of a variety of quantities of interest (e.g., overall COVID-19 death rate, proportion of unrecognized COVID-19 deaths, and baseline deaths assuming no circulation of COVID-19). Our modeling framework is also widely applicable for estimating the disease burden of other infectious diseases that suffer from under-counting issues (e.g., influenza and pneumonia). We also fitted the Poisson log-linear random-intercept model used in Iuliano et al. (2021) to the current mortality data using estimates from the binomial test-positive model as covariates. During March 2020 to April 2021, the estimated total number of unrecognized deaths among those aged years was 62,700 (95% CI: 58,600, 66,900). While the point estimate is comparable to our estimates of 58,200 (95% CI: 51,300, 64,900), our approach results in larger posterior interval width (13,600 versus 8,300). This is likely due to the incorporation of additional sources of uncertainty, such as estimation errors associated with the percent positive and spatial–temporal random effects. Also, Iuliano et al. (2021) assume a common temporal trend modeled using natural cubic splines with 5 degrees of freedom, while our approach models temporal trend more flexibly with a first-order random walk. However, for state-specific estimates, we found that our model sometimes provides smaller interval widths when the number of COVID-19 deaths is small, likely due to the use of random effects to borrow information across locations. By introducing latent Polya-Gamma variables and leveraging appealing properties of PG distributions, the computational cost associated with fully Bayesian inference for spatial–temporal binomial and negative-binomial models is greatly reduced. This will likely allow for subsequent analyses at finer spatial resolution (e.g., county-level) and with longer study period. Our analysis also only focused on those aged years, a population with high burden of COVID-19, which may be due to the high prevalence of comorbid conditions such as diabetes, cardiovascular diseases, and renal impairment. Analysis among younger age groups will involve modeling SARS-CoV-2 percent positive with smaller sample sizes and lower death counts, where leveraging spatial–temporal dependence may be particularly helpful. Our experience in modeling death counts in states with small population (Fig. 3, Fig. 4) also highlight the importance of quantifying uncertainties in estimates. On the other hand, the baseline mortality trends in younger age groups may exhibit weaker seasonality because of the lower rates of chronic diseases. This which may facilitate the statistical model to estimate residual temporal variation attributable to COVID-19 activity. Furthermore, in assessing the society and economic impacts of COVID-19, deaths in younger age groups are associated with larger years of potential life loss (YPLL), a commonly used for assessing premature deaths; though assumptions and uncertainties in values assigned to each age at death also play an important role in these calculations. There are several limitations of this analysis that should be acknowledged. First, the spatial–temporal binomial regression model for positive SARS-CoV-2 testing results only contained an intercept. Additional factors may be useful for predicting percent positive of SARS-CoV-2 test results among subpopulations, including sex, gender, race/ethnicity, medical condition, timing of vaccination, circulation of the Delta variant, and use of boosters (de Lusignan et al., 2020, Fan et al., 2020). The percent positive can then be used to estimate COVID-19 disease burden among specific high-risk subpopulations. Second, we assumed a constant autoregressive parameter in the binomial regression. The model with state-specific may be worth further investigations when spatially-varying temporal dependence is considered. Third, we assumed the associations between weekly mortality and 1-week and 2-week lagged percent positive to be constant across space and time. We explored allowing for month or state-specific regression coefficients to potentially capture differences due to timing of the pandemic or spatial heterogeneity, but found no improvement in model fit as measured by WAIC under both models. It is also possible to consider more parsimonious spatially-varying coefficient models to allow state-specific effects of percent positive. Fourth, we found estimated state-specific mortality trends may not capture peaks in some states (Fig. 3). This may be due to the use of a common temporal trends across states, even though WAIC does not suggest the dynamic spatial–temporal random effect model is better. Other flexible methods to capture space–time interaction, such as temporal splines with spatially-varying coefficients, warrant further investigations. We estimated that 26% of deaths attributable to COVID-19 were unrecognized among those aged years during the pandemic up to April 2021. We note that estimating attributable deaths using an excess death approach may capture indirect deaths associated with the pandemic, such as those related to mental health, if the temporal patterns of these indirect causes are correlated with percent positive. Understanding factors that contributed to regional and temporal differences in under-counting can provide important knowledge in improving and designing disease burden surveillance systems. For example, the observed temporal decreases in proportion of unrecognized COVID-19 deaths may be due to increase in diagnostic capacity and experience. This is particularly important in the future when widespread access to testing is not sustainable.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  16 in total

1.  Excess Deaths From COVID-19 and Other Causes in the US, March 1, 2020, to January 2, 2021.

Authors:  Steven H Woolf; Derek A Chapman; Roy T Sabo; Emily B Zimmerman
Journal:  JAMA       Date:  2021-04-02       Impact factor: 56.272

2.  Bayesian Zero-Inflated Negative Binomial Regression Based on Pólya-Gamma Mixtures.

Authors:  Brian Neelon
Journal:  Bayesian Anal       Date:  2019-06-11       Impact factor: 3.728

3.  Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020.

Authors:  Daniel M Weinberger; Jenny Chen; Ted Cohen; Forrest W Crawford; Farzad Mostashari; Don Olson; Virginia E Pitzer; Nicholas G Reich; Marcus Russi; Lone Simonsen; Anne Watkins; Cecile Viboud
Journal:  JAMA Intern Med       Date:  2020-10-01       Impact factor: 21.873

4.  Analysis of Excess Deaths During the COVID-19 Pandemic in the State of Florida.

Authors:  Moosa Tatar; Amir Habibdoust; Fernando A Wilson
Journal:  Am J Public Health       Date:  2021-02-18       Impact factor: 9.308

5.  Estimates of deaths associated with seasonal influenza --- United States, 1976-2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-08-27       Impact factor: 17.586

6.  Estimating under-recognized COVID-19 deaths, United States, march 2020-may 2021 using an excess mortality modelling approach.

Authors:  A Danielle Iuliano; Howard H Chang; Neha N Patel; Ryan Threlkel; Krista Kniss; Jeremy Reich; Molly Steele; Aron J Hall; Alicia M Fry; Carrie Reed
Journal:  Lancet Reg Health Am       Date:  2021-07-13

7.  Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study.

Authors:  Simon de Lusignan; Jienchi Dorward; Ana Correa; Nicholas Jones; Oluwafunmi Akinyemi; Gayatri Amirthalingam; Nick Andrews; Rachel Byford; Gavin Dabrera; Alex Elliot; Joanna Ellis; Filipa Ferreira; Jamie Lopez Bernal; Cecilia Okusi; Mary Ramsay; Julian Sherlock; Gillian Smith; John Williams; Gary Howsam; Maria Zambon; Mark Joy; F D Richard Hobbs
Journal:  Lancet Infect Dis       Date:  2020-05-15       Impact factor: 25.071

8.  Excess mortality during the Covid-19 pandemic: Early evidence from England and Wales.

Authors:  Sotiris Vandoros
Journal:  Soc Sci Med       Date:  2020-06-01       Impact factor: 4.634

9.  Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study.

Authors:  Keith R Neal; Sheena Ramsay; Brian J Thomson; William L Irving
Journal:  Gut       Date:  2007-03-07       Impact factor: 23.059

10.  Excess mortality in the United States during the first three months of the COVID-19 pandemic.

Authors:  R Rivera; J E Rosenbaum; W Quispe
Journal:  Epidemiol Infect       Date:  2020-10-29       Impact factor: 2.451

View more
  2 in total

1.  Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021.

Authors:  Yea-Hung Chen; Andrew C Stokes; Hélène E Aschmann; Ruijia Chen; Shelley DeVost; Mathew V Kiang; Suneil Koliwad; Alicia R Riley; M Maria Glymour; Kirsten Bibbins-Domingo
Journal:  PNAS Nexus       Date:  2022-06-08

2.  Excess all-cause mortality across counties in the United States, March 2020 to December 2021.

Authors:  Eugenio Paglino; Dielle J Lundberg; Ahyoung Cho; Joe A Wasserman; Rafeya Raquib; Anneliese N Luck; Katherine Hempstead; Jacob Bor; Irma T Elo; Samuel H Preston; Andrew C Stokes
Journal:  medRxiv       Date:  2022-05-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.